Novo Nordisk pushes FDA to stop GLP1 compounding citing "complexity' episode artwork

EPISODE · Oct 24, 2024 · 10 MIN

Novo Nordisk pushes FDA to stop GLP1 compounding citing "complexity'

from The Weight Loss Podcast

Today we discuss a major development: Novo Nordisk, the company behind WeGovy and Ozempic, is pushing the FDA to stop compounding pharmacies from manufacturing the compounded medications, citing the complexity of manufacture. Critics say it is just a ploy to secure profits.

NOW PLAYING

Novo Nordisk pushes FDA to stop GLP1 compounding citing "complexity'

0:00 10:17

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Frequently Asked Questions

How long is this episode of The Weight Loss Podcast?

This episode is 10 minutes long.

When was this The Weight Loss Podcast episode published?

This episode was published on October 24, 2024.

What is this episode about?

Today we discuss a major development: Novo Nordisk, the company behind WeGovy and Ozempic, is pushing the FDA to stop compounding pharmacies from manufacturing the compounded medications, citing the complexity of manufacture. Critics say it is just...

Can I download this The Weight Loss Podcast episode?

Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.
URL copied to clipboard!